
Switzerland’s Spiez Laboratory at the heart of WHO’s BioHub system
The Spiez Laboratory will be the first facility to be part of the WHO’s BioHub system, an infrastructure that will facilitate the timely sharing
The Greater Geneva Bern area
Covering almost half of Switzerland’s territory and sharing land borders with both France and Italy, as well as close proximity to Germany, Western Switzerland gives companies easy access to the 500 million consumers of the European market. Moreover, the region also counts on a multilingual and multicultural home population, 24 percent of whom are foreigners, and who represent a fantastic test market.
Other key advantages include well-developed industry clusters in a number of domains; a highly qualified, productive and multilingual workforce; consistent political stability; flexible labour laws; moderate tax rates; state-of-the-art infrastructure; a safe environment; and an exceptional quality of life.
The region’s industry expertise stretches from micro and non-technologies to life sciences, information and communications technologies, and clean technologies. There are a number of centres of excellence in these fields and a shared inter-cantonal objective to develop and maintain a competitive economy based on high value products and services. The GGBa aims to support the establishment of companies at the forefront of global innovation which can bring complementary products and services to the existing economy.
An Ideal Location
Important Advantages
Well-developed industry clusters in a number of domains
A highly-qualified, productive and multilingual workforce
Consistent political stability
Flexible labor laws
Moderate tax rates
State-of-the-art infrastructure
A safe environment
An exceptional quality of life
Attractive Networks for International Investors
Innovation is Key
The Spiez Laboratory will be the first facility to be part of the WHO’s BioHub system, an infrastructure that will facilitate the timely sharing
Biopôle has announced the launch of the “Biopôle Start-Up Fund”, a new fund dedicated to supporting the next generation of impact-driven life sciences entrepreneurs.
A biopharmaceutical company focused on developing innovative ophthalmic treatments, Oculis has announced the closing of an oversubscribed $ 57 million Series C financing round. Headquartered
Swiss biotech companies Berna Biotech Pharma and Swiss Biotech Center are joining forces to develop a second-generation vaccine against covid-19. The goal is to conduct
HubsGoGlobal is a platform under the PharmaBoardroom brand that focuses on the competitive advantages of the Hub and its value proposition in terms of strategic, operational, financial, talent and lifestyle aspects.
PharmaBoardroom provides industry trends, news and reports from all over the world. This site is for senior professionals who want to understand local and global markets.
Copyright: All rights reserved. No part of this site maybe reproduced in any form or by any means, whether electronic, mechanical or otherwise including photocopying, recording or any information storage or retrieval system without prior written consent of PharmaBoardroom. While every attempt is made to ensure the accuracy of the information contained in this website, neither PharmaBoardroom nor the authors accept any liabilities for errors and omissions. Opinions expressed in this report are not necessarily those of the authors.
2021 © PharmaBoardroom
BANNER REGISTER